Equities analysts expect that Omega Therapeutics Inc (NASDAQ:OMGA) will report ($0.49) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Omega Therapeutics’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.46). The firm is expected to issue its next earnings report on Friday, December 10th.
According to Zacks, analysts expect that Omega Therapeutics will report full-year earnings of ($2.60) per share for the current year, with EPS estimates ranging from ($3.07) to ($1.77). For the next year, analysts anticipate that the business will post earnings of ($3.53) per share, with EPS estimates ranging from ($3.92) to ($3.31). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Omega Therapeutics.
Omega Therapeutics (NASDAQ:OMGA) last released its quarterly earnings results on Friday, September 10th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($2.94).
Shares of NASDAQ:OMGA traded up $0.28 during midday trading on Wednesday, reaching $18.49. The company had a trading volume of 327 shares, compared to its average volume of 130,174. Omega Therapeutics has a 1-year low of $15.50 and a 1-year high of $24.29.
About Omega Therapeutics
Omega Therapeutics Inc is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc is based in CAMBRIDGE, Mass.
Featured Article: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.